Status
Conditions
Treatments
About
Clinically, all patients with interstitial lung disease(ILD) were observed, and relevant clinical data were collected. Bronchoscopic specimens were collected according to the condition of the enrolled patients, and the rapid on site evaluation(ROSE) was evaluated, combined with the metagenomic next generation sequencing(mNGS) results of these patients. To observe the etiology and biological characteristics of exacerbation in patients with interstitial lung disease.
All patients undergo polysomnography (PSG) and drug-induced sleep endoscopy(DISE). The biological specimens was obtained for molecular biology or other tests.We detected Claudin1, Claudin2, Claudin3, Claudin4, and IL22 as biomarkers to differentiate the diagnostic efficiency of OSA in ILD, ILD+OSA, OSA, and Ctrl groups, respectively
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
70 participants in 2 patient groups
Loading...
Central trial contact
Dan Liu; Jing Feng
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal